Thrombocytaaggregáció-gátló kezelés akut ischaemiás szindrómában. Tények és várakozások

Translated title of the contribution: Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The current practice of platelet aggregation inhibition in acute coronary syndrome is reviewed. The specific dosing and its clinical usefulness of each medication are considered. The author is drawing attention to the fact, that the dosing scheme used in the early phase 3 trials may not have been optimal as proven in later trials. The hyporeactivity against both acctilsalicilic acid and clopidogrel treatment is existing and maybe called resistance. Its clinical importance in clinical outcomes is to be determined in later investigations. Because of the probable relationship between resistance and clinical outcomes the measurement of platelet reactivity by a reliable rapid bedside tool may be important in the future. Also the new platelet aggregation inhibitors under development are reviewed.

Original languageHungarian
Pages (from-to)483-491
Number of pages9
JournalOrvosi Hetilap
Volume149
Issue number11
DOIs
Publication statusPublished - Mar 16 2008

Fingerprint

clopidogrel
Platelet Aggregation Inhibitors
Acute Coronary Syndrome
Platelet Aggregation
Blood Platelets
Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thrombocytaaggregáció-gátló kezelés akut ischaemiás szindrómában. Tények és várakozások. / Keltai, M.

In: Orvosi Hetilap, Vol. 149, No. 11, 16.03.2008, p. 483-491.

Research output: Contribution to journalArticle

@article{533c7d3943a644249f487d90db5f9986,
title = "Thrombocytaaggreg{\'a}ci{\'o}-g{\'a}tl{\'o} kezel{\'e}s akut ischaemi{\'a}s szindr{\'o}m{\'a}ban. T{\'e}nyek {\'e}s v{\'a}rakoz{\'a}sok",
abstract = "The current practice of platelet aggregation inhibition in acute coronary syndrome is reviewed. The specific dosing and its clinical usefulness of each medication are considered. The author is drawing attention to the fact, that the dosing scheme used in the early phase 3 trials may not have been optimal as proven in later trials. The hyporeactivity against both acctilsalicilic acid and clopidogrel treatment is existing and maybe called resistance. Its clinical importance in clinical outcomes is to be determined in later investigations. Because of the probable relationship between resistance and clinical outcomes the measurement of platelet reactivity by a reliable rapid bedside tool may be important in the future. Also the new platelet aggregation inhibitors under development are reviewed.",
keywords = "Acute coronary syndrome, Percutaneous coronary intervention, Platelet aggregation inhibition",
author = "M. Keltai",
year = "2008",
month = "3",
day = "16",
doi = "10.1556/OH.2008.28290",
language = "Hungarian",
volume = "149",
pages = "483--491",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "11",

}

TY - JOUR

T1 - Thrombocytaaggregáció-gátló kezelés akut ischaemiás szindrómában. Tények és várakozások

AU - Keltai, M.

PY - 2008/3/16

Y1 - 2008/3/16

N2 - The current practice of platelet aggregation inhibition in acute coronary syndrome is reviewed. The specific dosing and its clinical usefulness of each medication are considered. The author is drawing attention to the fact, that the dosing scheme used in the early phase 3 trials may not have been optimal as proven in later trials. The hyporeactivity against both acctilsalicilic acid and clopidogrel treatment is existing and maybe called resistance. Its clinical importance in clinical outcomes is to be determined in later investigations. Because of the probable relationship between resistance and clinical outcomes the measurement of platelet reactivity by a reliable rapid bedside tool may be important in the future. Also the new platelet aggregation inhibitors under development are reviewed.

AB - The current practice of platelet aggregation inhibition in acute coronary syndrome is reviewed. The specific dosing and its clinical usefulness of each medication are considered. The author is drawing attention to the fact, that the dosing scheme used in the early phase 3 trials may not have been optimal as proven in later trials. The hyporeactivity against both acctilsalicilic acid and clopidogrel treatment is existing and maybe called resistance. Its clinical importance in clinical outcomes is to be determined in later investigations. Because of the probable relationship between resistance and clinical outcomes the measurement of platelet reactivity by a reliable rapid bedside tool may be important in the future. Also the new platelet aggregation inhibitors under development are reviewed.

KW - Acute coronary syndrome

KW - Percutaneous coronary intervention

KW - Platelet aggregation inhibition

UR - http://www.scopus.com/inward/record.url?scp=41349084820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349084820&partnerID=8YFLogxK

U2 - 10.1556/OH.2008.28290

DO - 10.1556/OH.2008.28290

M3 - Article

C2 - 18343761

AN - SCOPUS:41349084820

VL - 149

SP - 483

EP - 491

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 11

ER -